Assessing the psychometric properties of generic (EQ-5D-5L) and disease-specific (KCCQ) quality of life in patients with hypertrophic cardiomyopathy in the AFFECT-HCM study
Open Access
- 1 January 2025
- journal article
- research article
- Published by BMJ in Open Heart
- Vol. 12 (1) , e003143
Abstract
Background: To assess the psychometric properties (content validity, reliability and construct validity) of generic and disease-specific health-related quality of life (HRQoL) instruments in patients with hypertrophic cardiomyopathy (HCM) and genotype-positive, phenotype-negative (G+/P−) individuals. Methods: As part of the multicentre, observational AFFECT-HCM study, HRQoL was measured using the generic EuroQoL-5 Dimension-5 Level (EQ-5D-5L) questionnaire, the Visual Analogue Scale (EQ VAS) and the disease-specific Kansas City Cardiomyopathy Questionnaire (KCCQ). The study included G+/P− individuals and HCM patients. EQ-5D-5L profiles were translated into EQ-5D values (utilities) using the Dutch value set. All instruments were evaluated regarding their general characteristics and health dimensions (content validity). Reliability was assessed using internal consistency (Cronbach’s alpha), response rate, floor/ceiling effects (percentage scoring highest/lowest), correlation and level of agreement between instruments (using Bland-Altman plots). Construct validity was assessed using the known-groups method to identify expected differences between relevant groups. Results: A total of 393 HCM patients and 78 G+/P− individuals were included in the psychometric assessment. Mean EQ-5D value in G+/P− individuals was 0.90 (81 EQ VAS, 93 KCCQ) and in HCM patients 0.84 (75 EQ VAS, 78 KCCQ). Ceiling effects were highest for EQ-5D values (51% in G+P; 32% in HCM), followed by the KCCQ (38% in G+P−; 12% in HCM) and the EQ VAS (8% in G+P−; 5% in HCM). KCCQ and EQ-5D values had the highest correlation (Spearman’s ρ=0.77) and showed good overall agreement according to the Bland-Altman plots. In HCM, EQ-5D values showed a slightly biased pattern with EQ-5D values scoring higher than the KCCQ. The KCCQ discriminated more nuances between relevant groups. Conclusions: Due to its simplicity and good overall agreement with the KCCQ—which showed slightly better discrimination—we propose from our data that the EQ-5D-5L is a suitable instrument for the HRQoL assessment in clinical practice in patients with HCM.Keywords
Funding Information
- Bristol Myers Squibb
- CVON (CARMA 01-003-2022-0358)
- Heart Foundation (2020B005)
This publication has 24 references indexed in Scilit:
- The Psychometric Performance of the Kansas City Cardiomyopathy Questionnaire-12 in Symptomatic Obstructive Hypertrophic CardiomyopathyJournal of Cardiac Failure, 2024
- Dapagliflozin and Quality of Life Measured Using the EuroQol 5-Dimension Questionnaire in Patients with Heart Failure with Reduced and Mildly Reduced/Preserved Ejection FractionEuropean Journal of Heart Failure, 2024
- Healthcare consumer acceptability of routine use of the EQ-5D-5L in clinical care: a cross-sectional surveyQuality of Life Research, 2024
- Patient-Reported Outcomes in Patients with CardiomyopathyCurrent Cardiology Reports, 2021
- Quality of life in men and women with heart failure: association with outcome, and comparison between the Kansas City Cardiomyopathy Questionnaire and the EuroQol 5 dimensions questionnaireEuropean Journal of Heart Failure, 2021
- Psychometric properties of the EQ-5D-5L: a systematic review of the literatureQuality of Life Research, 2020
- Assessing Health-Related Quality of Life in Heart Failure Patients Attending an Outpatient Clinic: A Pragmatic ApproachESC Heart Failure, 2018
- The “no problems”-problem: an empirical analysis of ceiling effects on the EQ-5D 5LQuality of Life Research, 2017
- EQ-5D and the EuroQol Group: Past, Present and FutureApplied Health Economics and Health Policy, 2017
- Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: A cross‐sectional cohort studyAmerican Journal of Medical Genetics Part A, 2009